What Is Selank?

Selank is a synthetic heptapeptide (seven amino acids: Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is derived from tuftsin, a naturally occurring tetrapeptide fragment of IgG that has immunomodulatory and some neurological activity. The researchers added a Pro-Gly-Pro sequence to the C-terminus specifically to slow enzymatic degradation and extend the peptide's active half-life in the brain.

Selank is approved as a pharmaceutical drug in Russia for anxiety and anxiety-asthenic disorders. It is not approved by the FDA, EMA, or any equivalent Western regulatory body. In the United States, it exists in a legal gray area — not scheduled, not approved, sold as a research compound.

In nootropic communities, Selank is usually discussed alongside Semax (a separate Russian peptide with a stimulating cognitive profile). The two are often stacked together on the premise that Semax provides cognitive activation that Selank softens with anxiolytic effects.

What Does the Research Say?

Evidence level: Preliminary — Selank has a plausible mechanism and clinical trials from Russian institutions, including the studies that supported its Russian pharmaceutical approval. Independent Western replication of those findings does not exist. The evidence base is real but geographically and institutionally concentrated.

Mechanism

Selank appears to modulate the GABAergic system, though not by binding directly to GABA-A receptors in the classical benzodiazepine sense. Russian researchers have described indirect potentiation of GABAergic transmission that produces anxiolytic effects without the sedation, tolerance, and dependence profile of benzodiazepines. Studies by Semenova et al. documented anxiolytic effects in rodent models (elevated plus maze, open field tests) that are phenotypically similar to benzodiazepines but without the withdrawal syndrome on discontinuation.

Serotonin pathways are also involved. Selank appears to upregulate expression of genes involved in serotonin transport and metabolism, particularly in the hippocampus, which may contribute to mood-stabilizing effects. BDNF (brain-derived neurotrophic factor) upregulation has been reported in some studies from the same group, invoked to explain possible neuroprotective and cognitive effects.

The enkephalinase inhibition mechanism (prolonging endogenous enkephalin activity, potentially contributing to anxiolysis and mood stabilization via endogenous opioid pathways) is proposed in some Russian literature but less central to current mechanistic claims.

Animal Studies

Multiple animal studies from Russian laboratories demonstrate anxiolytic effects, with reductions in anxiety-related behaviors across several established models. Effects on serotonin and dopamine turnover in the frontal cortex and striatum have been documented in rodents. These studies are consistent within the Russian research system, though they have not been replicated by independent groups outside Russia.

Human Studies

Clinical trials supporting Selank's Russian pharmaceutical approval were conducted at the V.V. Zakusov Research Institute of Pharmacology in Moscow. The trials involved patients with generalized anxiety disorder and anxiety-asthenic syndrome (a diagnostic category used in Russian psychiatry, roughly corresponding to mixed anxiety and neurasthenia). Studies used the Hamilton Anxiety Scale and similar instruments, and found improvements comparable to low-dose benzodiazepines without significant sedation or dependence.

Researchers associated with this work include Kozlovskaya MM and Zozulya AA at the Zakusov Institute. Uchakina ON and colleagues also published on Selank's effects on cytokine profiles in anxious patients.

The methodological limitations are important to name. Trial sizes were small (typically under 100 patients). Most studies were conducted by the groups that developed and commercially license the compound. Publication was primarily in Russian-language journals. These are not disqualifying flaws, but they explain why clinicians outside Russia treat the evidence base with caution. Independent replication is essentially absent.

Community and Anecdotal Reports

Selank has a substantial following on r/nootropics and r/Peptides. Users describe onset within 20 to 40 minutes of intranasal administration, with reports of "anxiety melting away without feeling drugged." The contrast with benzodiazepine sedation comes up constantly. Many users take it situationally for social anxiety, presentations, or high-stress events rather than daily.

The most common complaints are nasal burning with the drops and, for some users, a sense of mild fatigue. Vivid dreams are frequently reported. Reports of tolerance are mixed: some users run it for months without diminishing effects, others report reduced response within weeks. Sourcing quality is a persistent concern; research chemical vendors vary widely in purity and accurate concentration.

Common Uses

Anxiety and Generalized Anxiety Disorder

This is the primary clinical indication in Russia and the most common reported use globally. Selank's anxiolytic profile without sedation or dependence risk makes it appealing compared to benzodiazepines, particularly for situational use. Whether it would meet FDA approval standards for GAD on the basis of current evidence is unclear; the trial record is not at Western regulatory standards.

Cognitive Enhancement

Many users in nootropic communities take Selank for mild cognitive benefits (improved focus and working memory) rather than primarily for anxiety. The BDNF mechanistic claim provides a biological rationale, but human cognitive outcome data is thin. The cognitive effects reported are generally milder than what users describe with Semax.

Immune Modulation

Tuftsin, Selank's parent peptide, has immunomodulatory activity affecting phagocyte function and cytokine production. Selank retains some of this activity. Uchakina et al. documented effects on interferon production in anxious patients. The immune applications are a secondary consideration; this is not a primary reason most users seek it out.

Delivery Methods

Intranasal (Primary)

Intranasal delivery is the approved and standard route. The Russian pharmaceutical formulation is a 0.15% nasal drop solution. This route allows direct access via olfactory pathways to the CNS alongside systemic absorption, and it bypasses gastrointestinal proteolysis that would otherwise degrade the peptide. Nasal burning is the main practical downside.

The small molecular size of Selank and the Pro-Gly-Pro stability extension both contribute to reasonable nasal mucosal penetration. Sublingual use is reported anecdotally as an alternative for those who find the nasal route irritating, but no pharmacokinetic data exists for this route.

Injectable

Subcutaneous injection is used in some research contexts and by a subset of community users, but there is no approved injectable formulation. Published pharmacokinetic data on injectable Selank is minimal.

PEPVi does not provide dosing guidance. Dosing decisions should be made in consultation with a qualified healthcare provider.

Safety and Side Effects

The clinical trial record from Russian studies describes Selank as well-tolerated in short-term use. No serious adverse events were documented in the approval studies. The side effect profile in those trials was mild: nasal irritation, occasional headache, and transient fatigue.

No withdrawal syndrome comparable to benzodiazepines has been documented in either the clinical literature or community reports, which is one of the frequently cited reasons users prefer it. Long-term safety data does not exist. The trials ran weeks to months, not years.

Unknown areas include: effects of frequent use on GABAergic receptor expression over time, any interaction with prescribed benzodiazepines, and safety in populations not represented in the Russian trials (children, older adults, those with significant comorbidities). Community use in people tapering from benzodiazepines is reported; this is not an indication that has been studied.

There are no long-term human safety data for Selank from any source. Short-term use appears safe based on existing studies. That's the honest summary.

Selank is approved as a pharmaceutical drug in Russia and is manufactured by Peptogen Inc. It is not FDA-approved or EMA-approved. It is not a scheduled substance under US DEA regulations.

In the United States, Selank occupies legal gray territory: it is not approved for human use but is sold by research chemical vendors and some compounding pharmacies with "not for human consumption" labeling. The FDA's 2023 compounding restrictions affected the peptide landscape broadly, though Selank's status specifically was not among the most prominently debated cases.

Selank is one of the 12 peptides targeted in the current reclassification process. For details on what changes in July 2026, see What RFK's Peptide Reclassification Means for You.

Frequently Asked Questions

The anxiolytic effects are mechanistically different. Benzodiazepines bind directly to GABA-A receptors and produce rapid, dose-dependent sedation and anxiolysis, with documented tolerance and dependence with repeated use. Selank's GABAergic modulation is indirect and does not appear to produce the same dependence profile in the studies conducted. The subjective effect is consistently described as calming without sedation. Whether this distinction holds under long-term use in humans is not established.

Selank is primarily anxiolytic — users describe it as calming. Semax is primarily activating — users describe it as sharpening focus and motivation, sometimes with mild stimulant-like effects. They are often taken together precisely because the profiles are seen as complementary. See Semax: What the Research Says for more.

Russian clinical trials say yes for anxiety-asthenic disorder, with effects comparable to low-dose benzodiazepines. The evidence is real — it supported pharmaceutical approval — but it comes from a concentrated group of investigators at the developing institution, using trial designs and patient populations that don't map cleanly to Western RCT standards. Community reports are broadly consistent with the clinical data. Independent confirmation by researchers outside the original group would strengthen confidence considerably.

No. Selank is not FDA-approved and there is no approved prescription pathway for it in the United States. It is sold through research chemical vendors and some compounding pharmacies, neither of which provides the oversight and quality control of a licensed pharmaceutical supply chain.

Learn More

Sources

  1. Semenova TP, Kozlovskaya MM, Zuikov AV, et al. "Effect of Selank on exploratory behavior and emotional reactions in rats with different neurotypological characteristics." Bulletin of Experimental Biology and Medicine, 2010. — Rodent anxiety model data supporting the anxiolytic mechanism; representative of the Russian animal literature on Selank.

  2. Uchakina ON, Uchakin PN, Miasoedov NF, et al. "Immunomodulatory effects of Selank in patients with anxiety-asthenic disorders." Zh Nevrol Psikhiatr Im S S Korsakova, 2008. — Human study examining cytokine changes alongside anxiolytic effects; documents immune modulation in anxious patients.

  3. Zozulya AA, Neznamov GG, Siuniakov TS, et al. "Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia." Zh Nevrol Psikhiatr Im S S Korsakova, 2008. — Clinical trial data on Selank in GAD; primary evidence supporting Russian pharmaceutical approval.